Bioarray PGS+PGD Single Biopsy Kit

Bioarray has launched its PGS+PGD Single Biopsy kit which screens aneuploidies and identifies embryos with pathological mutation from a single biopsy sample. The kit uses next-generation sequencing technology and bioinformatics analysis to determine whether an embryo carries aneuploidies, such as trisomy of chromosome 21, and allow for users to reject embryos affected by the mutation and/or select those not affected. Users can expect results to be processed within three to five days.